Yes, investors have until May 26, 2026 to become lead plaintiffs in the ImmunityBio Securities Fraud Case—a deadline that applies specifically to investors who want to direct the shareholder lawsuit and select their own counsel. This May 26 deadline is the cutoff date for the Court to receive motions from investors with substantial financial losses who wish to serve as lead plaintiff. If you purchased ImmunityBio (NASDAQ: IBRX) stock between January 19, 2026 and March 24, 2026 and suffered losses, you have a limited window to take this step. Even if you don’t qualify as lead plaintiff or miss this deadline, you can still potentially participate in any recovery from the class action—but the procedural landscape changes after May 26.
The underlying case stems from allegations that ImmunityBio made false and misleading statements about its cancer immunotherapy drug Anktiva and its broader business operations and prospects. Following an FDA warning letter regarding Anktiva’s advertising claims, ImmunityBio stock dropped approximately 21%, triggering shareholder litigation. Multiple law firms, including Rosen Law Firm and Pomerantz Law Firm, have filed related actions. Understanding the May 26 deadline is crucial because it represents a hard cutoff for a specific legal role—one that carries weight in how the litigation will unfold.
Table of Contents
- What Was ImmunityBio Accused of, and When Did the Alleged Misconduct Occur?
- Understanding the Financial Impact and Why This Matters for Potential Recovery
- The Lead Plaintiff Deadline—What Does May 26, 2026 Really Mean?
- Who Qualifies as Lead Plaintiff, and How Do You File Before May 26?
- Common Misconceptions About Securities Class Actions and Your Rights
- Why Multiple Law Firms Are Involved in the ImmunityBio Case
- What Happens After May 26 and What’s Next in the Litigation Timeline
What Was ImmunityBio Accused of, and When Did the Alleged Misconduct Occur?
The immunitybio securities case centers on allegations that company defendants, including founder and controlling shareholder Patrick Soon-Shiong, made false and misleading statements about Anktiva’s capabilities and the company’s business operations and prospects. The statements allegedly lacked reasonable basis and misled investors about the drug’s potential and the company’s market position. These alleged misstatements were made during a specific class period: January 19, 2026 through March 24, 2026—roughly a two-month window when investors relied on this allegedly false information to make trading decisions.
The catalyst for the case came when the FDA issued a warning letter regarding Anktiva’s advertising and promotional claims. This regulatory action exposed the gap between what had been communicated to the market and what the FDA determined was actually supported by evidence. For investors who bought stock during this class period at inflated prices based on the misrepresentations, the subsequent 21% stock decline represented real financial loss. An investor who purchased $50,000 of IBRX stock in February 2026, for example, would have seen that position lose roughly $10,500 in value after the warning letter news broke.
Understanding the Financial Impact and Why This Matters for Potential Recovery
When ImmunityBio stock fell approximately 21% following disclosure of the FDA warning letter, thousands of shareholders suffered losses. The magnitude of this decline matters because it anchors the potential damages the company might owe. In securities fraud cases, defendants are generally liable for the difference between what investors paid for the stock (based on the false statements) and the price after the truth was revealed. The larger this differential, the larger the potential class action recovery pool.
However, not all shareholders qualify as class members. You must have purchased ImmunityBio stock between January 19, 2026 and March 24, 2026 to be part of the class action. If you bought the stock before January 19 or after March 24, your losses won’t be recoverable in this particular case, even if you held shares when they declined. Additionally, the amount recovered in the settlement—once one is eventually negotiated—will be divided among all eligible class members based on their losses. This means an investor with $100,000 in losses would recover proportionally more than an investor with $10,000 in losses, but the total pool is finite.
The Lead Plaintiff Deadline—What Does May 26, 2026 Really Mean?
May 26, 2026 is the deadline for investors to move the court to serve as lead plaintiff in the ImmunityBio class action. A lead plaintiff is the named shareholder who officially represents the entire class and has the authority to select counsel and approve key litigation decisions. This role carries significant responsibility and, in some cases, may require more active involvement than a typical class member. The deadline means you have approximately two months from today to submit a motion if you want to pursue this leadership position.
Being lead plaintiff offers a real advantage: you get to choose which law firm represents the class and effectively direct the litigation strategy. For investors with substantial losses, this can be meaningful because your selected counsel will negotiate the settlement and determine how aggressively to pursue the case. However, lead plaintiff also means being named in public court filings, potentially being deposed by defense counsel, and bearing scrutiny from the defendants. For most retail investors, the practical benefit of lead plaintiff status is limited—what matters more is whether the case is pursued vigorously and whether a fair settlement is reached. If you miss the May 26 deadline or don’t want the responsibility, you can still participate in the class action and share in any recovery; you simply won’t have the leadership role.
Who Qualifies as Lead Plaintiff, and How Do You File Before May 26?
To qualify as lead plaintiff, you must be a member of the class (meaning you purchased IBRX stock between January 19 and March 24, 2026) and meet the Court’s standards for representing the class. Typically, courts prefer lead plaintiffs with significant losses, as they have the strongest incentive to ensure vigorous prosecution of the case. A shareholder with $50,000 in losses is a stronger lead plaintiff candidate than one with $2,000 in losses, though each case is different.
To move the Court for lead plaintiff status before May 26, you’ll need to contact one of the law firms pursuing the case—Rosen Law Firm was the first filer, and Pomerantz Law Firm has also filed related actions. These firms will guide you through the motion process and explain whether your specific situation qualifies. The firms typically handle the paperwork and Court filings at no upfront cost to you; they’re paid from any eventual settlement. If you don’t take action by May 26 and the lead plaintiff position is filled by someone else, you can still participate in the class action and pursue recovery—you simply won’t have had input on which law firm leads the case.
Common Misconceptions About Securities Class Actions and Your Rights
One widespread misunderstanding is that you must be lead plaintiff to recover money. This is false. Whether or not you participate in the lead plaintiff motion, if you’re a class member with documented losses, you’re entitled to a share of any settlement achieved. Lead plaintiff is an optional role; class membership is automatic based on your purchase dates. Another misconception is that the deadline means you can’t join the class after May 26. That’s also incorrect—the May 26 deadline applies only to the lead plaintiff motion.
The class action itself will remain open for claims for much longer, typically through a claims period following settlement approval. A third misconception is that settling or recovering damages somehow suggests wrongdoing by you as an investor. Securities class actions are a standard mechanism for recovery when companies defraud shareholders; participating is no admission of poor judgment on your part. You relied on the company’s representations like any reasonable investor would. Additionally, some investors mistakenly believe they need to hire their own attorney or pay upfront legal fees to participate. Class action law firms work on contingency—they recover fees from the settlement amount if successful. If the case results in no recovery, you owe the law firm nothing.
Why Multiple Law Firms Are Involved in the ImmunityBio Case
Rosen Law Firm and Pomerantz Law Firm both filed securities lawsuits related to ImmunityBio. Rosen filed first, which gives it a procedural advantage and positions it favorably to be selected as lead counsel. However, Pomerantz’s involvement shows that the case has attracted serious attention from multiple litigation firms with track records in securities cases. Multiple filings are common in securities class actions when a major stock decline occurs; different firms pursue different angles or represent different investor groups.
Eventually, the Court will consolidate these cases into a single class action and select a lead law firm (likely Rosen, given its first-filer status). Investors in either filing can move to be lead plaintiff or simply participate in the class. If you’re contacted by one firm, you’re not obligated to stick with them for lead plaintiff purposes—you can express interest in a different firm’s representation if you prefer. What matters most is that qualified counsel is pursuing the case vigorously and that investors’ interests are protected through the settlement process.
What Happens After May 26 and What’s Next in the Litigation Timeline
After the May 26, 2026 lead plaintiff deadline passes, the case will move into its substantive phase: defendants will file motions to dismiss, discovery will begin (where both sides exchange documents and evidence), and settlement negotiations will likely commence. The timeline from here could span months or years depending on case complexity and settlement speed. Most securities class actions are resolved through settlement rather than trial, with negotiations often intensifying after significant motion practice.
Once a settlement is reached and approved by the Court, class members will be notified and given a period—typically 60 to 90 days—to submit claim forms documenting their losses. This is when you’ll receive your share of any recovery, determined by your share of the total class losses. For investors who suffered losses during the class period, keeping records of their purchase dates, prices, and sell prices is essential for making a valid claim later. Even if you do nothing by May 26, save your trading records and watch for future settlement notices from the Court.